blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2089061

EP2089061 - INHIBITION OF SOX9 FUNCTION IN THE TREATMENT OF PROTEOGLYCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS [Right-click to bookmark this link]
Former [2009/34]INHIBITION OF SOX9 FUNCTION FN THE TREATMENT OF PROTEOGL YCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS
[2015/15]
StatusNo opposition filed within time limit
Status updated on  08.07.2016
Database last updated on 03.10.2024
Most recent event   Tooltip08.12.2017Lapse of the patent in a contracting state
New state(s): LU		published on 10.01.2018  [2018/02]
Applicant(s)For all designated states
The University Of Western Ontario
Gordon Mogenson Building 100 Collip Circle Suite 105
London, ON N6G 4X8 / CA
[2009/34]
Inventor(s)01 / BROWN, Arthur
30 Dana Crescent
Thornhill, ON L4J 2R5 / CA
02 / GRIS, Paul
3674A Manns Chapel Road
Chapel Hill NC 27516 / US
 [2009/34]
Representative(s)HGF
HGF Limited
Mill House
North Street
York YO1 6JD / GB
[N/P]
Former [2015/36]HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ / GB
Former [2009/39]Harrison Goddard Foote
106 Micklegate York
YO1 6JX / GB
Former [2009/34]Harrison Goddard Foote
106 Micklegate
York, Yorkshire YO1 6JX / GB
Application number, filing date07816052.025.10.2007
[2009/34]
WO2007CA01902
Priority number, dateUS20060863202P27.10.2006         Original published format: US 863202 P
[2009/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008049226
Date:02.05.2008
Language:EN
[2008/18]
Type: A1 Application with search report 
No.:EP2089061
Date:19.08.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 02.05.2008 takes the place of the publication of the European patent application.
[2009/34]
Type: B1 Patent specification 
No.:EP2089061
Date:02.09.2015
Language:EN
[2015/36]
Search report(s)International search report - published on:CA02.05.2008
(Supplementary) European search report - dispatched on:EP18.08.2010
ClassificationIPC:A61K31/711, C07K16/28, G01N33/68, A61K48/00, A61K39/395, A61P25/00, C12Q1/00, C12Q1/68, C07H21/00, C12N15/12, C12N15/113, A61K39/00
[2015/15]
CPC:
C07K16/2845 (EP,US); A61K31/711 (EP,US); A61P13/12 (EP);
A61P19/04 (EP); A61P25/00 (EP); A61P27/02 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP); C12N15/113 (EP,US); G01N33/6887 (EP,US);
A61K2039/505 (EP,US); C12N2310/11 (EP,US); C12N2310/14 (EP,US);
G01N2500/10 (EP,US) (-)
Former IPC [2010/37]A61K31/711, C07K16/28, G01N33/68, A61K48/00, A61K39/395, A61P25/00, C12Q1/00, C12Q1/68, C07H21/00, C12N15/12
Former IPC [2009/34]A61K48/00, A61K31/711, A61K39/395, A61P25/00, C12Q1/00, C12Q1/68, C07H21/00, C12N15/12
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/36]
Former [2009/34]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:HEMMUNG DER SOX9-FUNKTION BEI DER BEHANDLUNG VON PATHOPHYSIOLOGISCHEN ZUSTÄNDEN IM ZUSAMMENHANG MIT PROTEOGLYKAN[2009/34]
English:INHIBITION OF SOX9 FUNCTION IN THE TREATMENT OF PROTEOGLYCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS[2015/15]
French:INHIBITION DE LA FONCTION SOX9 DANS LE TRAITEMENT D'ÉTATS PATHOPHYSIOLOGIQUES ASSOCIÉS À UN PROTÉOGLYCANE[2009/34]
Former [2009/34]INHIBITION OF SOX9 FUNCTION FN THE TREATMENT OF PROTEOGL YCAN-ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS
Entry into regional phase27.05.2009National basic fee paid 
27.05.2009Search fee paid 
27.05.2009Designation fee(s) paid 
27.05.2009Examination fee paid 
Examination procedure27.05.2009Examination requested  [2009/34]
16.03.2011Amendment by applicant (claims and/or description)
16.09.2011Despatch of a communication from the examining division (Time limit: M06)
21.03.2012Reply to a communication from the examining division
14.05.2013Despatch of a communication from the examining division (Time limit: M08)
20.12.2013Reply to a communication from the examining division
18.03.2015Communication of intention to grant the patent
27.07.2015Fee for grant paid
27.07.2015Fee for publishing/printing paid
27.07.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.09.2011
Opposition(s)03.06.2016No opposition filed within time limit [2016/32]
Fees paidRenewal fee
23.09.2009Renewal fee patent year 03
13.10.2010Renewal fee patent year 04
26.10.2011Renewal fee patent year 05
18.10.2012Renewal fee patent year 06
30.10.2013Renewal fee patent year 07
14.10.2014Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.10.2007
AT02.09.2015
BE02.09.2015
BG02.09.2015
CY02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
MT02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
TR02.09.2015
IE25.10.2015
LU25.10.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GB02.12.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
[2018/02]
Former [2017/39]HU25.10.2007
AT02.09.2015
BE02.09.2015
BG02.09.2015
CY02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
MT02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
TR02.09.2015
IE25.10.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GB02.12.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2017/03]AT02.09.2015
BE02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
IE25.10.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GB02.12.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/47]AT02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
IE25.10.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GB02.12.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/45]AT02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
IE25.10.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/39]AT02.09.2015
CZ02.09.2015
DK02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/36]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SI02.09.2015
SK02.09.2015
CH31.10.2015
LI31.10.2015
FR02.11.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/33]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SK02.09.2015
CH31.10.2015
LI31.10.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
DE03.05.2016
Former [2016/28]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
MC02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SK02.09.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
Former [2016/24]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SK02.09.2015
GR03.12.2015
IS02.01.2016
PT04.01.2016
Former [2016/23]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
NL02.09.2015
PL02.09.2015
RO02.09.2015
SE02.09.2015
SK02.09.2015
GR03.12.2015
IS02.01.2016
Former [2016/22]AT02.09.2015
CZ02.09.2015
EE02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
NL02.09.2015
PL02.09.2015
SE02.09.2015
GR03.12.2015
IS02.01.2016
Former [2016/21]AT02.09.2015
ES02.09.2015
FI02.09.2015
IT02.09.2015
LT02.09.2015
LV02.09.2015
PL02.09.2015
SE02.09.2015
GR03.12.2015
Former [2016/11]AT02.09.2015
ES02.09.2015
FI02.09.2015
LT02.09.2015
LV02.09.2015
PL02.09.2015
SE02.09.2015
GR03.12.2015
Former [2016/10]ES02.09.2015
FI02.09.2015
LT02.09.2015
LV02.09.2015
PL02.09.2015
SE02.09.2015
GR03.12.2015
Former [2016/09]FI02.09.2015
LT02.09.2015
LV02.09.2015
GR03.12.2015
Former [2016/07]LT02.09.2015
Documents cited:Search[XI]WO2005100552  (SANBIO INC [US], et al) [X] 1-3,7-10 * the whole document * [I] 4-6;
 [IP]  - GRIS PAUL ET AL, "Transcriptional regulation of scar gene expression in primary astrocytes.", GLIA 15 AUG 2007 LNKD- PUBMED:17597120, (20070815), vol. 55, no. 11, ISSN 0894-1491, pages 1145 - 1155, XP002595336 [IP] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1002/GLIA.20537
 [A]  - WEGNER ET AL, "From stem cells to neurons and glia: a Soxist's view of neural development", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.TINS.2005.08.008, (20051101), vol. 28, no. 11, ISSN 0166-2236, pages 583 - 588, XP005123801 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tins.2005.08.008
 [A]  - GRIS D ET AL, "TRANSIENT BLOCKADE OF THE CD11D/CD18 INTEGRIN REDUCES SECONDARY DAMAGE AFTER SPINAL CORD INJURY, IMPROVING SENSORY, AUTONOMIC, AND MOTOR FUNCTION", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US LNKD- DOI:10.1523/JNEUROSCI.5343-03.2004, (20040421), vol. 24, no. 16, ISSN 0270-6474, pages 4043 - 4051, XP009046075 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1523/JNEUROSCI.5343-03.2004
 [A]  - STOLT C CLAUS ET AL, "The Sox9 transcription factor determines glial fate choice in the developing spinal cord.", GENES & DEVELOPMENT 1 JUL 2003 LNKD- PUBMED:12842915, (20030701), vol. 17, no. 13, ISSN 0890-9369, pages 1677 - 1689, XP002595337 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1101/GAD.259003
 [A]  - SAVILLE L R ET AL, "A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX LNKD- DOI:10.1016/J.JNEUROIM.2004.07.002, (20041101), vol. 156, no. 1-2, ISSN 0165-5728, pages 42 - 57, XP004591400 [A] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jneuroim.2004.07.002
International search[X]WO03102130  (PFIZER PROD INC [US], et al);
 [XP]  - GRIS P. ET AL., "Transcriptional Regulation Of Scar Gene Expression In Primary Astrocytes", GLIA, (20070815), vol. 55, pages 1145 - 1155, XP008109655

DOI:   http://dx.doi.org/10.1002/glia.20537
 [AP]  - SUMI E. ET AL., "SRY-Related HMG Box 9 Regulates The Expression Of Col4a2 Through Transactivating Its Enhancer Element In Mesangial Cells", AM. J. PATHOL., (200706), vol. 170, pages 1854 - 1864, XP008109656

DOI:   http://dx.doi.org/10.2353/ajpath.2007.060899
by applicantUS5034506
    - P.E. NIELSON ET AL., SCIENCE, (1991), vol. 254, page 1497
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - YAMAUCHI S; MITA S; MATSUBARA T; FUKUTA M; HABUCHI H; KIMATA K; HABUCHI O, "Molecular cloning and expression of chondroitin 4-sulfotransferase", J BIOL CHEM, (2000), vol. 275, no. 12, pages 8975 - 81
    - ZUO J; NEUBAUER D; DYESS K; FERGUSON TA; MUIR D, "Degradation of chondroitin sulfate proteoglycan enhances the neurite- promoting potential of spinal cord tissue", EXP NEUROL, (1998), vol. 154, no. 2, doi:doi:10.1006/exnr.1998.6951, pages 654 - 62, XP003008298

DOI:   http://dx.doi.org/10.1006/exnr.1998.6951
    - FOK-SEANG, J.; L. C. SMITH-THOMAS ET AL., "An analysis of astrocytic cell lines with different abilities to promote axon growth", BRAIN RES, (1995), vol. 689, no. 2, doi:doi:10.1016/0006-8993(95)00575-B, pages 207 - 23, XP022256998

DOI:   http://dx.doi.org/10.1016/0006-8993(95)00575-B
    - GRIS, P.; A. TIGHE ET AL., "Transcriptional regulation of scar gene expression in primary astrocytes", GLIA, (2007), vol. 55, no. 11, pages 1145 - 55
    - WESTON, A. D.; R. A. S. CHANDRARATNA ET AL., "Requirement for RAR- mediated gene repression in skeletal progenitor differentiation", J. CELL BIOL., (2002), vol. 158, no. 1, doi:doi:10.1083/jcb.200112029, pages 39 - 51, XP002244028

DOI:   http://dx.doi.org/10.1083/jcb.200112029
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.